Merck KGaA, Pfizer's avelumab misses goal in gastric cancer trial

FRANKFURT (Reuters) - Germany's Merck KGaA said on Tuesday that its cancer immunotherapy avelumab, jointly developed with Pfizer, failed to improve overall survival compared with standard chemotherapy in a late-stage study on gastric cancer patients.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news